FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

CGMP Violations at Oregons Wild Harvest

FDA warns Redmond, OR-based Oregons Wild Harvest about CGMP violations in its manufacturing, packaging, labeling, and holding of dietary supplements.

latest-news-card-1
Human Drugs

Steps Toward Drug Quality Knowledge Management System

Several international pharmaceutical regulatory organizations, including FDA, issue a joint reflection paper on efforts toward building a pharmaceutic...

latest-news-card-1
Biologics

Positive Results in Pfizer RSV Vaccine Trial

Pfizer says it will seek regulatory approval this fall for its respiratory syncytial virus prefusion F vaccine candidate.

latest-news-card-1
Federal Register

Medical Device Export Information Collection

Federal Register notice: FDA sends to OMB an information collection extension entitled Export of Medical Devices; Foreign Letters of Approval.

latest-news-card-1
Human Drugs

WLF Post Looks at Pfizers Copay Subsidy Program

Writing in an online Washington Legal Foundation post, Goodwin Procter partner Matt Wetzel examines a recent appeals court decision that shot down Pfi...

latest-news-card-1
Medical Devices

FDA Approves Abbott Proclaim Plus System

FDA approves Abbotts new Precision Plus spinal cord stimulation system.

latest-news-card-1
Biologics

BioMarin Refiling BLA for Hemophilia A Gene Therapy

BioMarin Pharmaceutical says it will resubmit by the end of September its BLA for hemophilia A gene therapy Roctavian (valoctocogene roxaparvovec) gen...

Biologics

Califf Says No Panel Will Review Covid Boosters

FDA commissioner Robert Califf says there are no new questions on the recently submitted Covid-19 booster vaccines and the agency will not need an adv...

latest-news-card-1
Human Drugs

Comments on Breakthrough Therapy Recission Draft

Three stakeholders comment on an FDA draft guidance on rescinding breakthrough therapy designations.

latest-news-card-1
Human Drugs

Imbruvica Pediatric sNDA Approved by FDA

FDA approves a Pharmacyclics supplemental NDA for Imbruvica (ibrutinib) for certain pediatric patients over one year of age with chronic graft versus ...